Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309912 | 1.00 | IDO1 (0.34) | IDO1GPR119PDE4DPDE4APDE4B | |
| SCHEMBL1813203 | 1.00 | IDO1 (0.34) | IDO1GPR119PDE4DPDE4APDE4B | |
| SCHEMBL731338 | 0.93 | IDO1 (0.33) | IDO1 | |
| SCHEMBL731339 | 0.93 | IDO1 (0.33) | IDO1 | |
| SCHEMBL741130 | 0.89 | IDO1 (0.35) | IDO1GPR119PDE4DPDE4APDE4B | |
| SCHEMBL309454 | 0.81 | IDO1 (0.41) | IDO1GPR119HRH3NAMPT | |
| SCHEMBL309455 | 0.81 | IDO1 (0.41) | IDO1GPR119HRH3NAMPT | |
| SCHEMBL15178335 | 0.76 | IDO1 (0.41) | IDO1GPR119HRH3NAMPT | |
| SCHEMBL15178373 | 0.74 | IDO1 (0.43) | IDO1GPR119HRH3NAMPT | |
| SCHEMBL743916 | 0.74 | IDO1 (0.44) | IDO1GPR119HRH3NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2120569-B1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2111406-B1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK SHARP & DOHME (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8093389-B2 | e.g. 1-[(1-Ethyl-4-methoxy-1H-benzimidazol-6-yl)carbonyl]-6-(1H-tetrazol-5-yl)spiro[chroman-2,4'-piperidine]-4-one; acetyl CoA carboxylase inhibitors; antidiabetic, hypoglycemic agent; metabolic syndrome, fatty liver, hyperlipemia, obesity, diabetes, bulimia, malignant neoplasm or infectious diseases | MERCK SHARP & DOHME CORP. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1910375-B1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7935712-B2 | Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090131464-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-7410976-B2 | Spirochromanone derivatives | MERCK & CO., INC. (US) | 2008-08-12 | — | — | US | disclosed |
| WO-2008088689-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171761-A1 | Substituted spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2008-07-17 | — | — | US | disclosed |
| US-20070021453-A1 | Novel spirochromanone derivatives | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | AKR1C3, CBR3, AKR1C4 | IDO1 280/4885GPR119 1243/4885PDE4D 4650/4885 |
| US-20070021453-A1 | Novel spirochromanone derivatives | HSD17B7, CYP11B2, CYP11B1 | IDO1 4844/4885GPR119 303/4885PDE4D 1997/4885 |
| US-20090131464-A1 | SPIROCHROMANONE DERIVATIVES AS ACETYL COENZYME A CARBOXYLASE (ACC) INHIBITORS | ACACA, ACACB, ACAT1 | IDO1 4750/4885GPR119 1937/4885PDE4D 2972/4885 |
| US-20080171761-A1 | Substituted spirochromanone derivatives | CBR3, CBR1, CNKSR1 | IDO1 537/4885GPR119 2925/4885PDE4D 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.